Notably, tofacitinib, the inhibitor drug targeting TYK2, is indicated for the treatment of ulcer colitis (a subtype of IBD) [29], while baricitinib, also targeting TYK2, is approved for the treatment of COVID-19. This evidence concerns the gene TYK2 and inflammatory bowel disease.